XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
We compare index funds and target date funds for retirement to help you decide based on time horizon, risk tolerance, costs, and tax considerations.
26,044 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Matrixport’s fear index shows mounting pessimism as Bitcoin whipsaws in a volatile market. While downside risk remain...
Starting with $1,000 can jumpstart a lasting investing habit. This guide shows practical ways to pick the best stocks...
As the trillion private credit market swells, a new risk signal emerges: more loans are under tighter, unrealized ter...
In 2025, Mackenzie Scott gave away $7.2 billion, setting a new standard for billionaire philanthropy and pushing her ...
U.S.-Israel strikes on Iran trigger sharp market moves as Trump calls regime change, raising the stakes for investors...
Bitcoin prices retreat toward $60,000 while the Fear & Greed Index hits Extreme Fear. Here’s how traders assess risk,...
New Census Bureau data reveals a stark generational imbalance: aging baby boomers dominate assets while younger Ameri...
A 68-year-old retiree donates appreciated stock to a charity after being influenced by mackenzie scott’s giving inspi...
NVIDIA defies traditional logic by trading on cheaper earnings multiples than its non-tech counterpart while leading ...
Looking for a simple, durable path to cash flow and growth? This article breaks down three reliable dividend stocks h...
Palantir has cooled off after a blazing run, but analysts say there's still meaningful upside. This guide breaks down...